Stay updated with breaking news from Ken Culver. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
19.04.2024 - Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an ... Seite 1
The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...
With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.